Trial · NCT03434028
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Death Before Discharge Home by Day 90 | From randomization to discharge home up to and including day 90. | The primary outcome was death from any cause before discharge home by day 90. Point estimates were from Kaplan-Meier curves. There were 109 deaths and 5 patients with censored data the restrictive fluid group and 116 deaths and 4 patients with censored data in the liberal group. We defined home as the same setting or a setting similar to the one where the patient resided before becoming ill. Thus, if a patient originated from a private residence and was discharged from the hospital to a rehabilitation setting, we assessed for vital status until return to the private residence.Vital status was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI). |
| Secondary | Organ Support Free Days | 28 days after randomization | Defined as a patient being alive and without assisted breathing, new renal replacement therapy, or vasopressors (excluding vasopressor use prior to 48 hours). Any day that a patient is alive and without organ support will represent days alive and free of organ support. |
| Secondary | Ventilator Free Days (VFD) | 28 days after randomization | Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days. |
| Secondary | Renal Replacement Free Days | 28 days after randomization | The number of calendar days between randomization and 28 days later that the patient is alive and without renal replacement therapy. Patients who died prior to day 28 are assigned zero renal replacement free days. |
| Secondary | Vasopressor Free Days | From study day 2 through day 28 | The number of calendar days between day 2 (eligibility starting 48 hours post randomization) and 26 days later that the patient is alive and without the use of vasopressor therapy. Patients who died prior to day 28 are assigned zero vasopressor free days. |
| Secondary | ICU Free Days | 28 days after randomization | Defined as the number of days spent alive out of the ICU to day 28. |
| Secondary | Hospital Free Days to Discharge Home | 28 days after randomization | Days alive post hospital discharge through day 28. Patients who die on or prior to day 28 are assigned zero hospital free days. |
| Secondary | New Intubation With Invasive Mechanical Ventilation by 28 Days | 28 days after randomization | Patients who receive invasive mechanical ventilation via endotracheal or tracheostomy tube, except those intubated solely for a procedure and extubated within 24 hours, through to study day 28 meet this endpoint. Non-invasive mechanical ventilation will not be included as an outcome. This is a binary outcome. |
| Secondary | Initiation of Renal Replacement Therapy | 28 days after randomization | Patients receiving (new) renal replacement therapy through day 28. Patients with chronic renal replacement therapy initiated prior to the current sepsis illness were not eligible to meet this endpoint. |
| Secondary | Kidney Disease: Change in Creatinine-based Global Outcomes (KIDGO) Score Between Baseline and 72 Hours | 72 hours after randomization | Assessment of renal function using the KDIGO staging system (using serum creatinine criteria only) between baseline and 72 hours post randomization to assess for de novo acute kidney injury (AKI) (e.g., meeting criteria for AKI by KDIGO criteria) or worsening AKI (e.g., increasing severity). Patients on chronic renal replacement therapy were not eligible for this endpoint determination. Scoring of 1-3 (using serum creatinine levels; a higher score indicates worsening kidney function): 1. creatinine level 1.5-1.9 times baseline OR \>/= 0.3 mg/dl (\>/= 25.5 umol/l) increase 2. creatinine level 2.0-2.9 times baseline 3. creatinine level 3.0 times baseline OR increase in serum creatinine to \>/=4.0mg/dl (\>/= 353 umol/l) OR initiation of renal replacement therapy |
| Secondary | Change in SOFA (Sepsis Related Organ Failure Assessment) Score | 72 hours after randomization | SOFA score was calculated at enrollment and at 72 hours using clinically available data.Total score: 0-4 points; 4 = worst outcome. Values not available at baseline were assumed normal. 72 hours assessment: Closest previously known value was carried forward for missing values. SOFA Scoring Breakout (lower scores mean a better outcome; clinically significant organ failure for CLOVERS was defined as a SOFA score 2 or more points higher than baseline): * Coagulation( Platelets, ×10³/µL): Score = 0: \>150; 1: \</= 150; 2: \</= 100; 3: \</= 50; 4: \</= 2 * Liver (Bilirubin, mg/dL): Score: 0: \<1.2; 1: 1.2-1.9; 2: 2.0-5.9; 3: 6.0-11.9; 4: \>11.9 * Cardiovascular(Hypotension): Score: 0: no hypotension; 1: Mean arterial pressure \<70 mmHg; 2: Dopamine\</=5 OR any dobutamine; 3: Dopanime \>5, epinephrine \</=0, or Norepi \</=0.1; 4: Dop \>15, epi \>0.1, or norepi \>0.1 * Renal (Creatinine, mg/dL or urine output, ml/d): Score: 0: \<1.2; 1: 1.2-1.9; 3: 2.0-3.4; 3: 3.5-4.9 or \<500; 4: \>4.9 or \<200 |
| Secondary | Development of ARDS | 7 days after randomization | Presence and severity of ARDS is determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio and confirmation of ARDS through chest x-ray reviews. |
| Secondary | New Onset Atrial or Ventricular Arrhythmia | 28 days after randomization | The occurrence of one or more episodes (sustained for more than 1 minute for SVT and AF, \> 15 seconds for VT) during through day 28 will be recorded. |
| Secondary | Death From Any Cause at Any Location by Day 90 | From randomization to and including day 90 | Subjects were contacted at day 90 to ascertain their survival status via telephone contact with the patient or family members or by a review of medical records and publicly available data sources. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03434028/registered